KLRK1 and acute myeloid leukemia: Importantly, no induction of NKG2D-ligand expression was observed in healthy PBMC treated with VPA (Figure 7B), suggesting a therapeutic window to specifically upregulate NKG2D-ligand expression in AML blasts.